Soluble CD25 in serum: a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis

Higher-dose Anakinra Is Effective in a Case of Medically Refractory Macrophage Activation Syndrome

(2013) P. J. KAHN et al.   JOURNAL OF RHEUMATOLOGY

Rapid and Sustained Remission of Systemic Juvenile Idiopathic Arthritis-Associated Macrophage Activation Syndrome Through Treatment With Anakinra and Corticosteroids

(2012) Normi Bruck et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Macrophage activation syndrome in children with systemic onset juvenile idiopathic arthritis: clinical experience from northwest India

(2011) Surjit Singh et al.   RHEUMATOLOGY INTERNATIONAL

Defective phosphorylation of interleukin-18 receptor β causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis

(2009) Wilco de Jager et al.   ARTHRITIS AND RHEUMATISM

Systemic JIA: new developments in the understanding of the pathophysiology and therapy

(2009) Sebastiaan J. Vastert et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Macrophage activation syndrome in 13 children with systemic-onset juvenile idiopathic arthritis

(2008) Hua-Song Zeng et al.   World Journal of Pediatrics